Genitourinary Cancer
Feature
Are oncologists ready to confront a second wave of COVID-19?
Conference Coverage
Durable efficacy with MK-6482 in VHL-associated RCC
MK-6482 produced responses in patients with Von Hippel-Lindau disease-associated renal cell carcinoma and non-renal lesions.
Conference Coverage
Clinical factors and treatment tied to COVID-19 mortality in cancer patients
Analyses of CCC19 data revealed factors linked to mortality in patients with COVID-19 and cancer.
Clinical Insights
The scope of under- and overtreatment in older adults with cancer
From the Journals
Cancer disparities: One of the most pressing public health issues
“The burden of cancer is not shouldered equally by all segments of the U.S. population,” the AACR states.
From the Journals
Global stomach cancer deaths decline as colorectal cancer deaths stagnate, rise
Data suggest fewer people are dying from stomach cancer, but in some countries, the risk of colorectal cancer death is increasing or declining...
From the Journals
Predicting complications of cytoreductive nephrectomy in metastatic RCC
Registry data revealed factors associated with intraoperative and postoperative complications.
Conference Coverage
Nivo-cabo combo joins advanced RCC treatment ranks
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Conference Coverage
Metformin may delay prostate cancer progression, randomized trial suggests
The data are “hypothesis generating” but not definitive, according to a study discussant.
From the Journals
If PPIs are onboard, atezolizumab may not work for bladder cancer
Proton pump inhibitor use was associated with worse overall and progression-free survival among patients on atezolizumab.